Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Trial

Abstract

Topiramate treatment at daily doses of approximately 100 mg resulted in statistically significant improvements compared with placebo in mean monthly migraine/migrainous and migraine headache days. Topiramate is safe and generally well tolerated in this group of subjects with chronic migraine, a burdensome condition with important unmet treatment needs. Safety and tolerability of topiramate were consistent with experience in previous clinical trials involving the drug.